Transplanted neural stem cells (NSCs) developed by Stemedica Cell Technologies, Inc., a company at the forefront of adult allogeneic stem cell manufacturing, research and development have been successful in treating rats with spinal cord injury (SCI). The research, conducted by Ivan Cheng, M.D., Assistant Professor in the Department of Orthopedic Surgery, Stanford University School of Medicine, was showcased at the North American Spine Society Annual Meeting in Chicago, IL on November 2, 2011. Dr. Cheng’s paper was called ‘Functional Assessment of Acute Local Versus Distal Transplantation of Human Neural Stem Cells Following Spinal Cord Injury’. The findings are a significant discovery in the field of spinal cord research.
Twenty-four subjects paraplegic subjects received either an injection of Stemedica’s ischemic tolerant human NSCs adjacent to the site of injury (local injection), or an intrathecal injection (lumbar puncture) of NSCs distal to the site of injury. Control subjects received an injection of control media alone either local or distal to the injury site. The rats were assessed following injury and then every week for six weeks.
According to Dr. Cheng, “The acute transplantation of NSCs into the rat’s injured spinal cord lead to significant functional recovery. This occurred whether the cells were injected either locally or distally. This preclinical research holds promise for patients in that we may be able to inject Stemedica NSCs through a traditional lumbar puncture in the acute phase after their injury.”
Stemedica’ adult stem cells are used at Angeles Hospital within a sponsored clinical trial. To learn more about how this partnership could benefit you and your health condition please contact us using the form on the right.